XML 40 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements - Assets and Liabilities at Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Recurring    
Assets:    
Assets, fair value $ 249,335 $ 188,764
Liabilities:    
Liabilities, fair value 10,343 14,245
Recurring | Current contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,618 4,618
Recurring | Current contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 86 86
Recurring | Long-term contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,783 3,783
Recurring | Long-term contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 1,503 1,503
Recurring | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 1,089 3,971
Recurring | Liability for amounts owed to former licensees    
Liabilities:    
Liabilities, fair value 264 284
Recurring | Short-term investments    
Assets:    
Assets, fair value 240,864 181,041
Recurring | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 3,877 3,877
Recurring | Investment in Warrants    
Assets:    
Assets, fair value 4,594 3,846
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Assets, fair value 33,886 5,742
Liabilities:    
Liabilities, fair value 264 284
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for amounts owed to former licensees    
Liabilities:    
Liabilities, fair value 264 284
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments    
Assets:    
Assets, fair value 29,292 1,896
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Warrants    
Assets:    
Assets, fair value 4,594 3,846
Recurring | Significant Other Observable Inputs (Level 2)    
Assets:    
Assets, fair value 211,572 179,145
Liabilities:    
Liabilities, fair value 1,089 3,971
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 1,089 3,971
Recurring | Significant Other Observable Inputs (Level 2) | Liability for amounts owed to former licensees    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments    
Assets:    
Assets, fair value 211,572 179,145
Recurring | Significant Other Observable Inputs (Level 2) | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Investment in Warrants    
Assets:    
Assets, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Assets, fair value 3,877 3,877
Liabilities:    
Liabilities, fair value 8,990 9,990
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,618 4,618
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 86 86
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities - Crystal    
Liabilities:    
Liabilities, fair value 3,783 3,783
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities - CyDex    
Liabilities:    
Liabilities, fair value 1,503 1,503
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Liability for amounts owed to former licensees    
Liabilities:    
Liabilities, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments    
Assets:    
Assets, fair value 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Note Receivable - Viking Therapeutics    
Assets:    
Assets, fair value 3,877 3,877
Recurring | Significant Unobservable Inputs (Level 3) | Investment in Warrants    
Assets:    
Assets, fair value 0 $ 0
Metabasis | Long-term contingent liabilities-Metabasis    
Liabilities:    
CVR payable to Metabasis $ 3,800